Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Patterson

Showing results (241-250 of 277) with videos related to

Pageof 28
Sort By:
Cancer Research|February 11, 2010
The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3Christopher P Guise, Maria R Abbattista, Rachelle S Singleton, et al.
Cancer Gene Therapy|February 9, 2021
Use of an optimised enzyme/prodrug combination for Clostridia directed enzyme prodrug therapy induces a significant growth delay in necrotic tumoursAlexandra M Mowday, Ludwig J Dubois, Aleksandra M Kubiak, et al.
Chest|May 22, 2021
ResponseEvan J Zasowski, Matteo Bassetti, Francesco Blasi, et al.
Journal of the American Heart Association|August 1, 2019
Angina Severity, Mortality, and Healthcare Utilization Among Veterans With Stable AnginaMina Owlia, John A Dodson, Jordan B King, et al.
JCO Clinical Cancer Informatics|September 27, 2021
Ascertainment of Veterans With Metastatic Prostate Cancer in Electronic Health Records: Demonstrating the Case for Natural Language ProcessingPatrick R Alba, Anthony Gao, Kyung Min Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2007
Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104Adam V Patterson, Dianne M Ferry, Shelley J Edmunds, et al.
Journal of Medicinal Chemistry|September 8, 2025
Design, Synthesis and Biological Evaluation of 7-(1-Methyl-1<i>H</i>-indole-3-yl)-5<i>H</i>-pyrrolo[2,3-<i>b</i>]pyrazine Derivatives as Novel Covalent pan-FGFR Inhibitors to Overcome Clinical ResistanceWuqing Deng, Xiaojuan Chen, Ling Yan, et al.
Molecules (Basel, Switzerland)|October 27, 2020
Subcellular Location of Tirapazamine Reduction Dramatically Affects Aerobic but Not Anoxic CytotoxicityChris P Guise, Maria R Abbattista, Robert F Anderson, et al.
Journal of Medicinal Chemistry|September 29, 2022
Discovery of Isoform-Selective Akt3 Degraders Overcoming Osimertinib-Induced Resistance in Non-Small Cell Lung Cancer CellsFang Xu, Xin Zhang, Zhipeng Chen, et al.
Circulation. Cardiovascular Interventions|February 18, 2022
Ankle- and Toe-Brachial Index for Peripheral Artery Disease Identification: Unlocking Clinical Data Through Novel MethodsJulia E Friberg, Abdul H Qazi, Brenden Boyle, et al.
Pageof 28

Showing results (241-250 of 277) with videos related to

Sort By:
Pageof 28
Cancer Research|February 11, 2010
The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3Christopher P Guise, Maria R Abbattista, Rachelle S Singleton, et al.
Cancer Gene Therapy|February 9, 2021
Use of an optimised enzyme/prodrug combination for Clostridia directed enzyme prodrug therapy induces a significant growth delay in necrotic tumoursAlexandra M Mowday, Ludwig J Dubois, Aleksandra M Kubiak, et al.
Chest|May 22, 2021
ResponseEvan J Zasowski, Matteo Bassetti, Francesco Blasi, et al.
Journal of the American Heart Association|August 1, 2019
Angina Severity, Mortality, and Healthcare Utilization Among Veterans With Stable AnginaMina Owlia, John A Dodson, Jordan B King, et al.
JCO Clinical Cancer Informatics|September 27, 2021
Ascertainment of Veterans With Metastatic Prostate Cancer in Electronic Health Records: Demonstrating the Case for Natural Language ProcessingPatrick R Alba, Anthony Gao, Kyung Min Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2007
Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104Adam V Patterson, Dianne M Ferry, Shelley J Edmunds, et al.
Journal of Medicinal Chemistry|September 8, 2025
Design, Synthesis and Biological Evaluation of 7-(1-Methyl-1<i>H</i>-indole-3-yl)-5<i>H</i>-pyrrolo[2,3-<i>b</i>]pyrazine Derivatives as Novel Covalent pan-FGFR Inhibitors to Overcome Clinical ResistanceWuqing Deng, Xiaojuan Chen, Ling Yan, et al.
Molecules (Basel, Switzerland)|October 27, 2020
Subcellular Location of Tirapazamine Reduction Dramatically Affects Aerobic but Not Anoxic CytotoxicityChris P Guise, Maria R Abbattista, Robert F Anderson, et al.
Journal of Medicinal Chemistry|September 29, 2022
Discovery of Isoform-Selective Akt3 Degraders Overcoming Osimertinib-Induced Resistance in Non-Small Cell Lung Cancer CellsFang Xu, Xin Zhang, Zhipeng Chen, et al.
Circulation. Cardiovascular Interventions|February 18, 2022
Ankle- and Toe-Brachial Index for Peripheral Artery Disease Identification: Unlocking Clinical Data Through Novel MethodsJulia E Friberg, Abdul H Qazi, Brenden Boyle, et al.
Pageof 28